Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns

Pieter M. H. Nierop1 · Boris Galjart1 · Diederik J. Höppener1 · Eric P. van der Stok1 · Robert R. J. Coebergh van den Braak2 · Peter B. Vermeulen3 · Dirk J. Grünhagen1 · Cornelis Verhoef1

Received: 1 February 2019 / Accepted: 4 March 2019 / Published online: 6 March 2019
© The Author(s) 2019

Abstract
The majority of patients recur after resection of colorectal liver metastases (CRLM). Patients with CRLM displaying a desmoplastic histopathological growth pattern (dHGP) have a better prognosis and lower probability of recurrence than patients with non-dHGP CRLM. The current study evaluates the impact of HGP type on the pattern and treatment of recurrences after first resection of CRLM. A retrospective cohort study was performed, including patients with known HGP type after complete resection of CRLM. All patients were treated between 2000 and 2015. The HGP was determined on the CRLM resected at first partial hepatectomy. The prognostic value of HGPs, in terms of survival outcome, in the current patient cohort were previously published. In total 690 patients were included, of which 492 (71%) developed recurrent disease. CRLM displaying dHGP were observed in 103 patients (21%). Amongst patients with dHGP CRLM diagnosed with recurrent disease, more liver-limited recurrences were seen (43% vs. 31%, p = 0.030), whereas patients with non-dHGP more often recurred at multiple locations (34% vs. 19%, p = 0.005). Patients with dHGP CRLM were more likely to undergo curatively intended local treatment for recurrent disease (adjusted odds ratio: 2.37; 95% confidence interval (CI) [1.46–3.84]; p < 0.001) compared to patients with non-dHGP. The present study demonstrates that liver-limited disease recurrence after complete resection of CRLM is more often seen in patients with dHGP, whereas patients with non-dHGP more frequently experience multi-organ recurrence. Recurrences in patients with dHGP at first CRLM resection are more likely to be salvageable by local treatment modalities, but no prognostic impact of HGPs after salvage therapy for recurrent disease was found.

Keywords Colorectal liver metastases · Histopathological growth patterns · Salvageable recurrences · Biomarker · Prognostication

Introduction
After hepatic resection for colorectal liver metastases (CRLM) the majority of patients experiences recurrence of disease. Despite advances in the treatment of CRLM, recurrence rates reach up to 70% [1–5]. Approximately 40% of the patients with recurrent disease is again eligible for local treatment modalities [4, 6–8]. If disease biology allows the recurrence to be treated locally again, survival outcomes similar to the first local treatment of metastases are seen [1, 4, 6–13]. In case of a recurrence not amenable to local treatment prognosis is limited [4, 7, 8, 13]. In addition, clinical risk factors currently used for the prediction of prognosis after first hepatic resection for CRLM, have not proven equally useful in prognostication after repeat resection for recurrent CLRM [14].
Histopathological growth patterns (HGP)s describe the transition border of CRLM to the normal liver parenchyma [15]. The assessment of HGPAs has been standardised in international consensus guidelines [16] and multiple studies have reported the effect of HGPAs on prognosis in patients with resectable CRLM [16–22]. We recently described the largest patient cohort to date and found that the desmoplastic HGP (dHGP) is associated with favourable overall survival, progression free survival compared to its non-desmoplastic counterpart (non-dHGP) [23]. In the current study we aimed to identify in the same cohort of patients potential explanations for this survival difference. Differences in recurrence pattern (intra- versus extrahepatic) and/or treatment of recurrent disease (local vs. systemic) might possibly account for the difference in survival outcomes between HGPAs. Therefore, the current study investigates the pattern of first recurrence and the salvageability of recurrent disease after first partial hepatectomy for CRLM in the context of HGPAs.

Methods

Patients

The current study was approved by the medical ethics committee of the Erasmus University Medical Centre Rotterdam (MEC 2018-1743). All consecutive patients that underwent first surgical treatment for CRLM between 2000 and 2015 at the Erasmus MC Cancer Institute were considered for inclusion. The prognostic value of HGPAs, in terms of survival outcome, in the current patient cohort were previously published [23]. Patients selected for this study had to be completely free of all known macroscopic disease at some point following first resection of CRLM in order to be eligible for inclusion. A positive resection margin (R1) was defined as tumour cells (i.e. microscopic residual disease) at the resection margin and therefore patients with an R1 resection were eligible for inclusion. Patients with unknown HGP type were excluded.

Design and outcomes

Data on patient characteristics, primary tumour, CRLM and recurrence were extracted from a prospectively maintained database. H&E tissue sections were retrospectively analysed for HGP assessment. Disease free survival (DFS) was defined as the time in months between the first hepatic resection for CRLM and diagnosis of recurrence or death. Post-recurrence survival (PRS) was defined as the time in months between diagnosis of recurrence after first hepatic resection for CRLM and death. When alive patients were censored at date of last follow-up. Local therapy with curative intent was defined as resection, ablation and/or radiation therapy after which the patient was considered to be free of disease.

Treatment and follow-up after first partial hepatectomy

Perioperative chemotherapy for resectable CRLM is not standard of care in the Netherlands, since no OS benefit has been found in randomised setting [24]. Therefore preoperative chemotherapy at the Erasmus MC Cancer Institute is only considered in case of borderline resectable, more than four and/or synchronous CRLM. Some patients, however, received chemotherapy in referring hospitals prior to referral. Patients do not receive postoperative chemotherapy. Follow-up is performed up to 5 years after resection of CRLM. The follow-up consists of carcinoembryonic antigen (CEA) monitoring every 3 months for the entire follow-up duration and imaging every 6 months in the first 3 years and annually in the fourth and fifth year. In case of elevated CEA levels (>('5 µg/L) or a rise in CEA levels (>25%) imaging is performed. When uncertainty with regard to the diagnosis of disease recurrence exists, biopsies are taken as confirmation. As with primary treatment for CRLM, treatment strategy for recurrent disease is established by a multidisciplinary board. The decision whether local therapies (resection, ablation, stereotactic body radiation) are considered beneficial for patients, depends on two factors: time to recurrence and localisation of recurrences.

Regarding time to recurrence, it was previously demonstrated that patients with a disease-free interval of less than 6 months again undergoing local treatment for the recurrence have poor survival outcomes [25]. Therefore, when patients present with recurrent disease within 6 months after resection of CRLM, patients first receive systemic chemotherapy before local therapy is considered. Systemic therapy normally consists of oxaliplatin- or irinotecan-based treatment regimens. Typically, three courses are administered followed by restaging and local therapy in case of partial response or stable disease. In case of progressive disease, patients are switched to second line chemotherapeutic regimens. When patients present with recurrent disease beyond 6 months after primary liver resection for CRLM and the lesions are treatable with local therapy, these patients are planned for local therapy accordingly. Again, no adjuvant chemotherapy is administered. Patients presenting with recurrent disease not eligible for local treatment receive palliative treatment.

Provided that the interval between first liver resection and recurrence is greater than 6 months, or less than 6 months, but at least stable disease after three courses of chemotherapy is observed, then localisation of recurrences is a decisive factor in the clinical decision making in these patients. The currently handled standard at our centre is, that when recurrent disease is liver-limited and it can be resected with
sufficient remnant liver, local treatment of the colorectal liver metastases should be attempted. In addition, local treatment is deemed feasible when concurrent oligometastatic extrahepatic is present. When extrahepatic disease is present in > 1 organ, local treatment is deemed futile.

**HGP assessment**

The HGPs were determined on the CRLM resected at the first hepatectomy. The HGP of CRLM describes the tumour-liver interface. Three different types of HGPs have been described; the desmoplastic (dHGP), the replacement (rHGP) and the rare pushing HGP (pHGP) [16]. The latter two (rHGP and pHGP) can be taken together as non-dHGP, since recent findings indicate that patients with CRLM that display any proportion non-dHGP at the interface have impaired prognosis compared to patients with pure dHGP [23]. In this study, international consensus guidelines for HGP assessment of liver metastases were utilised to determine the HGPs [16]. HGP determination was jointly executed by at least three trained observers (PN, BG, DH, ES, RC, PV). The observers were blinded for clinical data and outcome during HGP assessment. Some CRLM display multiple HGPs, therefore the complete interface of all available H&E tissue sections of all CRLM in every patient were examined. Only if pure dHGP was observed, patients were categorised as such. All other patient displaying any non-dHGP were categorised as non-dHGP. In accordance with the consensus guidelines, not all tissue sections are suitable for HGP assessment. If less than 20% of the interface is assessable, if the tissue section is of insufficient quality or when no vital tumour is present, the HGP cannot be determined.

**Statistical analysis**

Categorical data were presented using counts and percentages. Continuous data were reported with medians and corresponding interquartile range (IQR). Differences in proportions were evaluated with the Chi-squared test. Medians were compared using the Mann–Whitney U test. Median follow-up time for survivors was estimated by means of the reversed Kaplan–Meier method. Survival estimates were obtained using the Kaplan–Meier method, computed until 60 months and compared with the log rank test. Uni- and multivariable Cox regression analysis was performed to correct for potential confounding. Results of the Cox regression analyses were expressed in hazard ratios (HR) and corresponding 95% confidence intervals (CI). Uni- and multivariable binary logistic regression analysis was performed to evaluate possible predictors for unsalvageable recurrence. Results of the logistic regression analyses were expressed in odds ratios (OR) and corresponding 95% CI. In both the binary logistic regression and the Cox univariable regression models, all variables potentially related to salvageability of recurrence and/or overall survival were considered. All variables with p-values < 0.100 on univariable analysis were entered in the multivariable models. All statistical tests were two-sided and p-values < 0.05 were considered statistically significant. All analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL) and R version 3.5.1 (http://www.r-project.org).

**Results**

**Patients and disease free survival**

During the study period 964 patients were treated surgically for CRLM at the Erasmus MC Cancer Institute. HGP determination was performed in 732 patients (76%). Patients were excluded due to: no (complete) resection of CRLM (n = 100), missing H&E tissue sections (n = 55), ablative therapy only (n = 21) or non-suitable H&E tissue sections for HGP determination (n = 56). Of these 732 patients, 690 were completely free of all known disease at some point following first resection of CRLM and were included in the study. Hence, 42 patients were excluded (n = 24 primary tumour never resected after liver-first approach due to progressive metastatic disease, n = 18 extrahepatic disease never treated locally). Among the included patients, there were 173 (25%) with dHGP and 517 with non-dHGP (75%). Median follow-up for survivors was 76 months (IQR: 45–116). In total 492 patients (71%) had disease recurrence. A flowchart of the patient inclusion is displayed in Fig. 1. Baseline characteristics of all 690 patients compared for HGP are reported in Table 1. At baseline there were several differences between patients with dHGP compared to patients non-dHGP, especially in terms of primary tumour characteristics (lymph node status and adjuvant treatment) and CRLM characteristics (disease-free interval, CEA, size of largest CRLM, resection margin and preoperative treatment).

**Recurrence: survival, pattern and treatment**

A smaller proportion of patients with dHGP had disease recurrence compared to patients with non-dHGP (60% vs. 75%). Median DFS of patients with dHGP was 17 months (IQR: 7–not reached) compared to 10 months (IQR: 5–28) in patients with non-dHGP. The DFS significantly differed between both groups (p < 0.001, Fig. 2). In total 492 patients had disease recurrence after first resection of CRLM. The median time to recurrence in these 492 patients with recurrent disease was 8 months (IQR: 5–14). This was 9 months (IQR: 6–14) in patients...
with dHGP compared to 8 months (IQR: 4–13 months) in patients with non-dHGP. At 6 months after first liver resection, 57% of patients with non-dHGP developing recurrences was disease-free, while 71% of patients with dHGP tumours developing recurrences was disease-free at this point in time. Data on the pattern of first recurrence stratified for HGP are reported in Table 2. Patients with dHGP at first partial hepatectomy more often had an intrahepatic only recurrence (43% vs 31%, p = 0.030) whereas patients with non-dHGP more often had a multi-organ (≥2) recurrence (34% vs 19%, p = 0.005). Of all 492 patients with a recurrence, 224 (46%) were again treated with curative intent. Patients with dHGP were more often treated with curative intent for the recurrence (59% vs. 42%, p = 0.002). After correction for potential confounders, dHGP at first partial hepatectomy remained a significant predictor for salvageable recurrence (OR: 2.37, p < 0.001). Significant predictors negatively associated with salvageability were a right-sided primary tumour (OR: 0.36, p < 0.001), a node positive primary tumour (OR: 0.57, p = 0.008) and larger CRLM at first partial hepatectomy (OR: 0.92, p = 0.036) (Table 3).

As the higher rate of intrahepatic only recurrences in the dHGP group might explain the higher likelihood of curatively intended salvage treatment additional analyses have
|                          | Total N = 690 | dHGP N = 173 | Non-dHGP N = 517 | p-value |
|--------------------------|--------------|--------------|------------------|---------|
| **Gender**               |              |              |                  |         |
| Male                     | 445 (65%)    | 109 (63%)    | 336 (65%)        | 0.637   |
| Female                   | 245 (36%)    | 64 (37%)     | 181 (35%)        |         |
| **Age**                  |              |              |                  |         |
| Median (IQR)             | 65 (58–71)   | 65 (56–72)   | 64 (58–71)       | 0.984   |
| **ASA**                  |              |              |                  |         |
| ASA I-II                 | 617 (91%)    | 153 (89%)    | 464 (91%)        | 0.351   |
| ASA > II                 | 63 (9%)      | 19 (11%)     | 44 (9%)          |         |
| Missing                  | 10 patients  |              |                  |         |
| **Primary tumour characterisitics** |          |              |                  |         |
| Location                 |              |              |                  |         |
| Right-sided              | 116 (17%)    | 30 (17%)     | 86 (17%)         | 0.927   |
| Left-sided               | 302 (44%)    | 76 (44%)     | 226 (44%)        |         |
| Rectum                   | 256 (37%)    | 62 (36%)     | 194 (38%)        |         |
| Double tumour            | 16 (2%)      | 5 (3%)       | 11 (2%)          |         |
| **pTumour stage**        |              |              |                  |         |
| pT0-2                    | 134 (20%)    | 39 (23%)     | 95 (19%)         | 0.239   |
| pT3-4                    | 546 (80%)    | 132 (77%)    | 414 (81%)        |         |
| Missing                  | 10 patients  |              |                  |         |
| **Nodal status**         |              |              |                  |         |
| N0                       | 270 (40%)    | 79 (47%)     | 191 (38%)        | 0.035*  |
| N+                       | 407 (60%)    | 90 (53%)     | 317 (62%)        |         |
| Missing                  | 13 patients  |              |                  |         |
| **Adjuvant chemotherapy primary tumour** |              |              |                  |         |
| No                       | 587 (85%)    | 160 (93%)    | 427 (83%)        | 0.002*  |
| Yes                      | 103 (15%)    | 13 (8%)      | 90 (17%)         |         |
| **CRLM characteristics** |              |              |                  |         |
| Synchronous CRLM         |              |              |                  |         |
| No                       | 329 (48%)    | 264 (51%)    | 65 (38%)         | 0.002*  |
| Yes                      | 361 (52%)    | 253 (49%)    | 108 (62%)        |         |
| **Disease-free interval (months)** |              |              |                  |         |
| Median (IQR)             | 2 (0–17)     | 0 (0–13)     | 5 (0–18)         | 0.006*  |
| **Number of CRLM**       |              |              |                  |         |
| Median (IQR)             | 2 (1–4)      | 2 (1–4)      | 2 (1–4)          | 0.886   |
| **Size of largest CRLM (cm)** |          |              |                  |         |
| Median (IQR)             | 3.1 (2.0–4.5)| 2.5 (1.8–4.2)| 3.3 (2.3–4.8)    | <0.001* |
| Missing                  | 2 patients   |              |                  |         |
| **Preoperative CEA (µg/L)** |          |              |                  |         |
| Median (IQR)             | 14.0 (4.7–50.0)| 7.6 (3.2–30.0)| 16.2 (5.1–53.0)| <0.001* |
| Missing                  | 28 patients  |              |                  |         |
| **Fong CRS**             |              |              |                  |         |
| Low                      | 408 (61%)    | 101 (61%)    | 307 (61%)        | 0.924   |
| High                     | 262 (39%)    | 64 (39%)     | 198 (39%)        |         |
| Incomplete CRS           | 20 patients  |              |                  |         |
| **Bilobar metastases**   |              |              |                  |         |
| No                       | 418 (61%)    | 106 (61%)    | 312 (60%)        | 0.830   |
| Yes                      | 272 (39%)    | 67 (39%)     | 205 (40%)        |         |
| **Preoperative CTx**     |              |              |                  |         |
| No                       | 365 (53%)    | 68 (39%)     | 297 (57%)        | <0.001* |
| Yes                      | 325 (47%)    | 105 (61%)    | 220 (43%)        |         |
been performed, specifically excluding patients with intrahepatic recurrences only. We subsequently conducted the same multivariable logistic regression analysis as conducted previously and, despite excluding patients with liver-limited recurrences, still found a statistically significant association between dHGP and salvage treatment of the recurrence (adjusted OR: 3.16, p < 0.001).

**Post-recurrence survival**

Median PRS after diagnosis of recurrence was 28 months (IQR: 15–59 months). Patients treated with curative intent had a median PRS of 56 months (IQR: 27–84 months) compared to 19 months (IQR: 11–32 months) for patients receiving palliative treatment (p < 0.001). After stratification for treatment intent, no difference in PRS was observed between patients with dHGP and non-dHGP (both p-values > 0.25, Fig. 3).

**Discussion**

The current study demonstrates that patients with dHGP at first CRLM resection more often develop an intrahepatic only recurrence, whereas patients with non-dHGP more often experience multi-organ recurrence. Importantly, dHGP at first CRLM resection is independently associated with salvageable recurrences after first partial hepatectomy for CRLM. Prognosis after salvage treatment for recurrent disease is not impacted by HGP type determined at first resection of CRLM.

Unfortunately, the majority of patients develops a recurrence after curatively intended resection of CRLM [1–12]. The prognosis of patients with recurrent disease strongly depends on whether local treatment can still be performed. Disease load and tumour biology largely determine if local therapy is possible and beneficial [4, 10, 12, 26]. As this study shows, that recurrences in patients with dHGP at first CRLM resection are more likely to be salvageable, this potentially explains the observed outcome difference between patients with dHGP and non-dHGP. Several studies have suggested that dHGP is associated with favourable tumour characteristics and a lower recurrence rate [16–23].

---

**Table 1 (continued)**

|                        | Total N = 690 | dHGP N = 173 | Non-dHGP N = 517 | p-value |
|------------------------|--------------|-------------|-----------------|---------|
| Resection margin       |              |             |                 |         |
| R0                     | 585 (85%)    | 158 (92%)   | 427 (83%)       | 0.004*  |
| R1                     | 102 (15%)    | 14 (8%)     | 88 (17%)        |         |
| Missing                | 3 patients   |             |                 |         |
| Extra hepatic disease  |              |             |                 |         |
| No                     | 629 (91%)    | 157 (91%)   | 472 (91%)       | 0.827   |
| Yes                    | 61 (9%)      | 16 (9%)     | 45 (9%)         |         |
| Major liver resection  |              |             |                 |         |
| <3 complete segments   | 455 (66%)    | 122 (71%)   | 333 (64%)       | 0.142   |
| ≥3 complete segments   | 235 (34%)    | 51 (30%)    | 184 (36%)       |         |
| Recurrence after first resection CRLM | | | | |
| No                     | 198 (29%)    | 70 (40%)    | 128 (25%)       | <0.001* |
| Yes                    | 492 (71%)    | 103 (60%)   | 389 (75%)       |         |

*Indicates significant p-value
Percentages do not always add up to 100% due to rounding

ASA American Society of Anaesthesiologists, CEA carcinoembryonic antigen, CRLM colorectal liver metastases, CRS clinical risk score, CTx Chemotherapy, HGP histopathological growth pattern, IQR inter-quartile range, R1 irradical resection margin
The more favourable tumour behaviour of dHGP CRLM was further acknowledged in this study, as patients with dHGP at first CRLM resection more often experience intra-hepatic only recurrence, whereas patients with non-dHGP more often develop multi-organ metastases. This also partially explains why salvage therapy was more often performed in these patients, as repeat resection of isolated recurrences is often feasible [1, 4, 6, 7, 9–12]. There were several differences observed at baseline between patients with dHGP compared to patients with non-dHGP in terms of clinical risk. Patients with non-dHGP had a greater proportion lymph node positive primaries, larger CRLM, and more often an R1 resection margin. These differences might also have attributed to the greater risk of multi-organ recurrences that are less likely salvageable with local treatment modalities in patients with non-dHGP. However, after correction for potentially confounding factors, dHGP remained significantly associated with salvageable recurrences. In addition, this study shows that patients with dHGP less often develop a recurrence and, if they do, the recurrence is also more often salvageable with local treatment modalities.

| Table 2 Recurrence pattern |
|-----------------------------|
| Total (N = 492) | dHGP (N = 103) | Non-dHGP (N = 389) | p-value |
|-----------------|----------------|-------------------|---------|
| Intrahepatic only | 166 (34%) | 44 (43%) | 122 (31%) | 0.030* |
| Pulmonary only | 104 (21%) | 22 (21%) | 82 (21%) | 0.951 |
| One other location only | 70 (14%) | 17 (17%) | 53 (14%) | 0.457 |
| Local recurrence primary only | 15 (3%) | 3 (3%) | 12 (3%) |
| Peritoneal only | 3 (1%) | 1 (1%) | 2 (1%) |
| Distant lymph nodes only | 26 (5%) | 7 (7%) | 19 (5%) |
| Other location only | 26 (5%) | 6 (6%) | 20 (5%) |
| Two or more locations | 152 (31%) | 20 (19%) | 132 (34%) | 0.005* |
| Intrahepatic and pulmonary only | 49 (10%) | 10 (10%) | 39 (10%) |
| Intrahepatic and 1 other only | 41 (8%) | 3 (3%) | 38 (10%) |
| Pulmonary and 1 other only | 25 (5%) | 1 (1%) | 24 (6%) |
| Peritoneal and 1 other only | 2 (1%) | 0 (0%) | 2 (1%) |
| Multi organ (> 2) | 35 (7%) | 6 (6%) | 29 (8%) |
| Treatment of recurrence with curative intent | 224 (46%) | 61 (59%) | 163 (42%) | 0.002* |

*Indicates significant p-value

| Table 3 Logistic regression for salvageable recurrence |
|--------------------------|
| Variable | Univariable | Multivariable |
|-------------|-------------|---------------|
| Odds ratio [95% CI] | P-value | Odds ratio [95% CI] | p-value |
| Age at resection CRLM (cont.) | 0.986 [0.968–1.004] | 0.122 | 0.986 [0.968–1.004] | 0.122 |
| ASA > II | 0.879 [0.470–1.642] | 0.685 |
| Right-sided primary | 0.416 [0.249–0.694] | 0.001* | 0.364 [0.211–0.628] | < 0.001* |
| pT3-4 | 0.534 [0.334–0.855] | 0.009* | 0.686 [0.409–1.151] | 0.153 |
| Node positive primary | 0.490 [0.336–0.715] | < 0.001* | 0.568 [0.375–0.860] | 0.008* |
| Disease free interval (cont.) | 1.011 [1.001–1.022] | 0.037* | 1.013 [1.003–1.024] | 0.014* |
| Number of CRLM (cont.) | 0.949 [0.880–1.023] | 0.171 |
| Diameter largest CRLM (cont.) | 0.932 [0.862–1.007] | 0.076 | 0.915 [0.842–0.994] | 0.036* |
| Preoperative CEA level (cont.) | 1.210 [0.849–1.727] | 0.292 |
| Preoperative chemotherapy | 1.000 [0.999–1.000] | 0.270 |
| R1 resection CRLM | 0.971 [0.607–1.554] | 0.903 |
| Extra hepatic disease | 0.864 [0.483–1.545] | 0.622 |
| Desmoplastic type tumours | 2.014 [1.295–3.132] | 0.002* | 2.370 [1.462–3.840] | < 0.001* |

*Indicates significant p-value

ASA American Society of Anaesthesiologists, CEA carcinoembryonic antigen, cont. continuous, CRLM colorectal liver metastases, R1 irradical resection margin
A frequently debated contraindication for local treatment of colorectal liver metastases is the simultaneous presence of extrahepatic disease. However, several recent (reviews of) retrospective series support resection of liver metastases and concurrent mono-organic extrahepatic disease in highly selected patients [27–30]. When extrahepatic disease is present in > 1 organ, the benefit of local treatment seems questionable as it holds outcome similar to systemic treatment alone [30]. As we demonstrated that multi-organ metastasis are more often found in patients with non-dHGP, we believe that this also partially explains why salvage treatment is less often performed in these patients. Moreover, several studies have demonstrated that some localisations of (recurrent) metastases (e.g. liver and concurrent para-aortic lymph node metastases [31, 32]) are associated with poor survival outcomes after surgery. Therefore, local therapies are often not considered beneficial in these patients. The true value of maximal tumour debulking in metastatic colorectal cancer will only be known after the completion of the ongoing ORCHESTRA trial (NCT01792934) in which patients are randomised between chemotherapy alone or the combination of chemotherapy and maximal tumour debulking.

As the scoring was performed jointly and the final HGP score was determined by consensus between all observers, no Kappa value for this specific study can be provided. However, in another recently submitted manuscript by our group we have found excellent Kappa indices (> 0.9) for discrimination between dHGP and non-dHGP [36].

This is the first paper demonstrating a significant association between distinct HGPs and differences in recurrence pattern in patients treated surgically for CRLM. Eefsen and colleagues [18] reported on the recurrence pattern in the context of HGPs but did not find an association. Importantly, the authors in that study applied an arbitrary cut-off value for the determination of the pre-dominant HGP. Recent insights have shown that the presence of any non-dHGP entails poor prognosis and no cut-off value for determination of the predominant HGP should be applied [23]. In addition, the number of patients with a recurrence in their study was limited and therefore a potential lack of power should also be considered. The current study handled no arbitrary cut-off value for pre-dominant HGP determination and describes a sufficiently large cohort, in which proper correction for confounding could be performed.

Most of the currently available risk factors for worse outcome after first resection of CRLM do not hold similar prognostic value when utilised for preoperative prognosis prediction at repeat resection of recurrent CRLM [14]. This indicates that there is a need for new prognostic markers in patients undergoing repeat partial hepatectomies for recurrent CRLM. This is the first study to evaluate the prognostic impact of HGPs of the CRLM resected at first liver resection for prognosis after repeat resection of CRLM. No difference in PRS was observed between patients with dHGP and non-dHGP. The reason that the HGP of the CRLM resected at first liver resection, rather than the HGP of recurrent CRLM resected at repeat resection, were used in the current study was twofold. Firstly, if the HGP at first resection had proven to be prognostic after repeat resection it would have become not only a predictive marker for prognosis after first resection, but also a pre-salvage treatment marker for local treatment of the recurrence. Secondly, this cohort also describes patients with an extrahepatic recurrence without
a concurrent hepatic recurrence and therefore no HGP of an recurrent CRLM could be utilised.

Recently RAS mutational status has also been associated with unsalvageable recurrences [4]. Unfortunately RAS and BRAF mutational status were unknown in the currently described patient cohort at time of resection. In an attempt to correct for this drawback, primary tumour location (right- vs. left-sided) was taken into account in the multivariable analysis. Right-sided tumours have been associated with the presence of KRAS [37, 38] and BRAF [37–40] mutations. Right-sidedness of the primary tumour was independently negatively associated with salvageability of recurrent disease in the present study. Despite correcting for primary tumour location (and thereby partially correcting for mutational status) HGP type remained statistically associated with salvageability of recurrent disease.

The limitations of the current study should be taken into account. Although data was extracted from a prospectively maintained database, HGP determination was performed retrospectively. Also, in 96 potentially eligible patients no HGP could be determined, which might have induced selection bias. The prognostic value of HGPs and their association with salvageability of recurrent disease after first resection of CRLM should therefore be validated, preferably in a prospective setting.

In conclusion, the present study confirms that over two-thirds of patients develop a recurrence after primary resection of CRLM. Disease recurrence confined to the liver is more often seen in patients with dHGP at first CRLM resection whereas patients with non-dHGP more frequently develop multi-organ recurrence. Importantly, recurrences in patients with dHGP at first CRLM resection are more likely to be salvageable by local treatment modalities. HGPs determined at first CRLM resection had no prognostic value after salvage therapy for recurrent disease.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schullick RD et al (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastases: an international multi-institutional analysis of 1669 patients. Ann Surg 250:440–448
2. Galjart B, van der Stok EP, Rothbarth J, Grunhagen DJ, Verhoef C (2016) Posttreatment surveillance in patients with prolonged disease-free survival after resection of colorectal liver metastasis. Ann Surg Oncol 23:3999–4007
3. Hamady ZZ, Lodge JP, Welsh FK, Toogood GJ, White A, John T et al (2014) One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg 259:543–548
4. Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T et al (2018) RAS mutation is associated with unsalvageable recurrence following hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 25:2457–2466
5. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580
6. Hof J, Wertenbroek MW, Peeters PM, Widder J, Sieders E, de Jong KP (2016) Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br J Surg 103:1055–1062
7. Oma M, Hasegawa K, Shindoh J, Yamashita S, Sakamoto Y, Makuuchi M et al (2016) Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. Surgery 159:632–640
8. Butte JM, Gonen M, Allen PJ, Peter Kingham T, Sofocleous CT, DeMatteo RP et al (2015) Recurrence after partial hepatectomy for metastatic colorectal cancer: potentially curative role of salvage repeat resection. Ann Surg Oncol 22:2761–2771
9. Andreou A, Brouquet A, Abdalla EK, Aloia TA, Curley SA, Vauthey JN (2011) Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford) 13:774–782
10. Mise Y, Imamura H, Hashimoto T, Suyama Y, Anoki T, Hasegawa K et al (2010) Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases. Ann Surg 251:902–909
11. Shaw IM, Rees M, Welsh FK, Bygrave S, John TG (2006) Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival. Br J Surg 93:457–464
12. Wicherts DA, de Haas RJ, Salloum C, Andreani P, Pascal G, Sotirov D et al (2013) Repeat hepatectomy for recurrent colorectal metastases. Br J Surg 100:808–818
13. Vigano L, Capassotti L, Lapointe R, Barroso E, Hubert C, Giuliani F et al (2014) Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6025 patients. Ann Surg Oncol 21:1276–1286
14. Schmidt T, Nienhuser H, Kuna C, Klose J, Strowitzki MJ, Buchler MW et al (2018) Prognostic indicators lose their value with repeated resection of colorectal liver metastases. Eur J Surg Oncol 44:1610–1618
15. Vermeulen PB, Colpaert C, Salgado R, Royers R, Hellemans H, Van Den Heuvel E et al (2001) Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol 195:336–342
16. van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illeman M, Frentzas S et al (2017) International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer 117:1427–1441
17. Brunner SM, Kesselring R, Rubner C, Martin M, Jeiter T, Boerner T et al (2014) Prognosis according to histochemical analysis of liver metastases removed at liver resection. Br J Surg 101:1681–1691
18. Eefsen RL, Vermeulen PB, Christensen UJ, Laerum OD, Mogensen MB, Rolf HC et al (2015) Growth pattern of colorectal liver metastasis as a marker of recurrence risk. Clin Exp Metastasis 32:369–381
19. Frentzas S, Simonneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E et al (2016) Vessel co-option mediates
resistance to anti-angiogenic therapy in liver metastases. Nat Med 22:1294–1302
20. Nielsen K, Rolff HC, Eefsen RL, Vainer B (2014) The morphological growth patterns of colorectal liver metastases are prognostic for overall survival. Mod Pathol 27:1641–1648
21. Siriwardana PN, Luong TV, Watkins J, Turley H, Ghazaley M, Galjart B, Nierop PMH, van der Stok EP, van den Braak R, Hopner DJ, Daelmans S et al. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis. 2019
22. Van den Eynden GG, Bird NC, Majeed AW, Van Laere S, Dirix LY, Vermeulen PB (2012) The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin Exp Metastasis 29:541–549
23. Galjart B, Nierop PMH, van der Stok EP, van den Braak R, Hopner DJ, Daelmans S et al. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis. 2019
24. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215
25. van der Pool AE, Lalmahomed ZS, de Wilt JH, Eggermont AM, Ijzermans JM, Verhoef C (2009) Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy. J Gastrointest Surg 13:890–895
26. Hill CR, Chagpar RB, Callender GG, Brown RE, Gilbert JE, Martin RC (2012) Recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol 19:139–144 nd, et al.
27. Hadden WJ, de Reuver PR, Brown K, Mittal A, Samra JS, Hugh TJ (2016) Resection of colorectal liver metastases and extracranial disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford) 18:209–220
28. Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT et al (2014) Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer 50:1747–1757
29. Leung U, Gonen M, Allen PJ, Kingham TP, DeMatteo RP, Jarnagin WR et al (2017) Colorectal cancer liver metastases and concurrent extracranial disease treated with resection. Ann Surg 265:158–165
30. Chua TC, Saxena A, Liauw W, Chu F, Morris DL (2012) Hepatectomy and resection of concomitant extracranial disease for colorectal liver metastases–a systematic review. Eur J Cancer 48:1757–1765
31. Adam R, de Haas RJ, Wicherts DA, Vibert E, Salloum C, Azoulay D et al (2011) Concomitant extracranial disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg 253:349–359
32. Pulitano C, Bodingbauer M, Aldrighetti L, de Jong MC, Castillo F, Schulick RD et al (2011) Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol 18:1380–1388
33. Ayez N, van der Stok EP, Grunhagen DJ, Rothbarth J, van Meerten E, Eggermont AM et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol 41:859–867
34. Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jager D, Buchler MW, Weitz J et al (2014) Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer 14:174
35. Groot Koerkamp B, Sadot E, Kemeny NE, Gonen M, Leal JN, Allen PJ et al (2017) Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol 35:1938–1944
36. Höppener* DJ, Nierop* PMH, Herpel E, Rahbari NN, Doukas M, Vermeulen PB et al. Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy. Submitted. 2019
37. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014; 106
38. Smith CG, Fisher D, Claes B, Maughan TS, Idziasszczyk S, Peutenman G et al (2013) Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. Clin Cancer Res 19:4104–4113
39. Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K et al (2018) Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg 153:e180996
40. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF et al (2014) BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 120:2316–2324

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.